期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

MRI表观扩散系数对激素受体阳性和阴性乳腺癌患者新辅助化疗疗效的评估 被引量：2

下载PDF
导出
摘要 目的:探讨MRI表观扩散系数(ADC)对激素受体阳性和阴性乳腺癌患者新辅助化疗(NAC)疗效的评估。方法:对2011年1月至2013年12月我院收治的42例乳腺癌患者进行NAC,其中激素受体阳性(HR+)25例,激素受体阴性(HR-)17例;根据疗效将患者分为有反应组(CR+PR)和无反应组(SD+PD),比较HR+和HR-乳腺癌患者的有反应率及NAC前和NAC 4个周期后ADC值变化。结果:所有患者均完成了4个周期的NAC,患者CR率4.8%(2/42),PR率71.4%(30/42),SD率21.4%(9/42),PD率2.4%(1/42);HR+组有反应率80.0%(20/25),HR-组有反应率70.6%(12/17),两组有反应率比较差异无统计学意义(P>0.05);HR+组NAC前、NAC 4个周期后的ADC值由(0.85±0.14)×10-3 mm2/s增加到(0.93±0.21)×10-3 mm2/s,差异有统计学意义(P<0.05),HR-组NAC前、NAC 4个周期后的ADC值由(0.99±0.40)×10-3mm2/s增加到(1.01±0.39)×10-3 mm2/s,差异无统计学意义(P>0.05)。结论:HR+乳腺癌在Ki67高表达或HER-2阳性(Luminal B型)的情况下,MRI ADC值可能是评估NAC疗效的敏感性指标。
作者 李富 曾健 孔震 李春燕 罗铭
机构地区 广西医科大学第一附属医院胃肠腺体外科 广西医科大学第一附属医院放射科
出处 《广西医科大学学报》 CAS 2015年第3期405-407,共3页 Journal of Guangxi Medical University
基金 广西壮族自治区卫生厅自筹经费科研课题资助项目(No.Z2011328)
关键词 乳腺癌 激素受体 新辅助化疗 磁共振成像 表观扩散系数 疗效
分类号 R445.2 [医药卫生—影像医学与核医学] R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1Chen JH, Feig BA, Hsiang DJ, et al. Impact of MRI evaluates neoadjuvant chemotherapy response on chan- ge of surgical recomm-endation in breast cancer[J].Ann Surg,2009,249(3):448-454.
  • 2Richard R, Thomassin I, Chapellier M, et al. Diffusion- weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cane- er[J]. Eur Radiol,2013,23(9):2 420-2.
  • 3431. Hammond MEH, Hayes DF, Dowsett M, et al. Ameri- can Society of Clinical Oncology/College of American Pathologists guideline recommendati-ons for immuno- histochemical testing of estrogen and progesterone re- ceptors in breast cancer(unabridged version)[J].Archi pathol Laboratory Medicine,2010,134(7):e48-e72.
  • 4Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors[J]. J Natl Cancer Inst, 2000,92 : 205-216.
  • 5尹波,刘莉,张碧云,李郁欣,张军,耿道颖.MRI在乳腺癌新辅助化疗残留病灶评价中的价值[J].实用放射学杂志,2013,29(9):1441-1444. 被引量：11
  • 6Jenoen LR, Garzon B, Heldahl MG, et al. Diffusion- weighted and dynamic contrast-enhanced MRI in evalu- ation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients[J]. J Magn Re- son Imaging,2011,34(5) : 1 099-1 109.
  • 7Galons JP, Altbach MI, Paine Murrieta GD, et al. Early increases in breast tumor xenograft water mobility in response to paelitaxel therapy detected by noninvasive difusion magnetic resonance imaging [J]. Neoplasia (New York), 1999,1 (2): 113-117.
  • 8Cheang MC,Chia SK,Voduc D,et al. Ki67 index,HER- 2 status, and prognosis of patients with luminal 13 breast cancer[J]. JNatl Cancer Inst, 2009, 101 (10).- 736-750.
  • 9Dede DS, Gumuskaya 13, Guler G, et al. Evaluation of changes in biologic markers ER,PR, HER-2 and Ki-67 index in breast cancer with administration of neoadju- vant dose dense doxorubicin, cyclophosph-amide fol- lowed by paelitaxel chemotherapy[J]. J BUON, 2013, 18(2) :366-371.
  • 10Mori N,Ota H, Mugikura S, et al. Luminal-type breast cancer: correlation of apparent diffusion coefficients with the Ki-67 labeling index[J]. Radiology, 2015,274 (1) :66-73.

二级参考文献10

  • 1Schmitz A C, Peters N H, Veldhuis W B, et al. Contrast-en hanced 3.0-T breast MRI for characterization of breast lesions increased specificity by using vascular maps[J]. Eur Radiol,2008 18(2):355--364.
  • 2Sweeting R S, Klauber Demore N, Meyers M O, et al. Young women with locally advanced breast cancer who achieve breast conservation after neoadjuvant chemotherapy have a low local recurrence rate[J]. Am Surg, 2011,77 (7) : 850 -- 855.
  • 3Johansen R,Jensen L R, Rydand J, et al. Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI[J]. J Magn Reson Imaging, 2009,29 (6):1300-- 1307.
  • 4Faverly D R G, Hendriks J H C L, Holland R. Breast carcinomas of limited extent frequency, radiologic-pathologic characteristics, and surgical margin requirements[J]. Cancer, 2001,91 (4) : 647 - 659.
  • 5Seymour M T, Moskovie E C,Walsh G,et al. Ultrasound assess- ment of residual abnormalities following primary chemotherapy for breast cancer[J]. Br J Cancer,1997,76(3) 371--376.
  • 6Oxner C R, Vora L, Yim, J, et al. Magnetic resonance imaging- guided breast biopsy in lesions not visualized by mammogram or ultrasound[J]. Am Surg, 2012,78 (10) 1087 -- 1090.
  • 7Boetes C, Mus R D,Holland R ,et al. Breast tumors: compara tive accuracy of MRimaging relative to mammography and US for demonstrating extent[J]. Radiology, 1995, 197 (3) : 743-- 747.
  • 8Boetes C, Veltman J,Van D L, et al. The role of MRI in invasive lobular carcinoma[J]. Breast Cancer Res Treat , 2004,86 ( 1 ) 31 --37.
  • 9Tse G M K,Chaiwun B,Wong K T, et al. Magnetic resonance imaging of breast lesions-a pathologic correlation [J ]. Breast Cancer Res Treat, 2007,103(1) :1--10.
  • 10周娟,邢旭东,李功杰,陆虹,盛复庚,张洪涛.动态增强磁共振成像对新辅助化疗后乳腺癌残余病灶的术前评估[J].实用放射学杂志,2012,28(10):1553-1556. 被引量：19

共引文献10

同被引文献18

引证文献2

二级引证文献5

广西医科大学学报
2015年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部